Vor Biopharma Inc. (VOR)
Vor Biopharma Inc. (VOR)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Segment expenses | NaN | 695,981 | NaN | NaN |
| Net loss | -219,585 | 1,722,858 | -812,684 | -1,606,155 |
| Depreciation expense | 28 | 23 | 2 | 2,862 |
| Acquisition of in-process research and development | NaN | NaN | NaN | 222,592 |
| Non-cash lease expense | 109 | 107 | 60 | 5,480 |
| Stock-based compensation | 8,870 | 7,106 | 8,029 | 3,777 |
| Transaction costs for issuance of pre-funded warrants | NaN | 0 | 643 | NaN |
| Change in fair value of warrant liabilities | 188,360 | -1,756,021 | 2,090,379 | NaN |
| Interest amortization on marketable securities | 488 | 34 | 11 | 22 |
| Loss on sale of property and equipment | 0 | 0 | 0 | -3,303 |
| Issuance of pre-funded warrants in connection with the acquisition of in-process research and development | NaN | 0 | 177,377 | NaN |
| Operating lease liabilities, net | -61 | -59 | -20 | -2,327 |
| Prepaid expenses and other current assets | 6,359 | 873 | 75 | -2,632 |
| Accounts payable, accrued liabilities and other current liabilities | -9,100 | 6,206 | 5,001 | -277 |
| Other assets | 20 | 2,114 | -151 | -1,963 |
| Net cash used in operating activities | -38,246 | -22,801 | -53,662 | -66,250 |
| Proceeds from sales of property and equipment | NaN | 0 | 0 | 799 |
| Purchases of marketable securities | 276,500 | 53,660 | 0 | 0 |
| Proceeds from maturities of marketable securities | 13,311 | 5,000 | 0 | 0 |
| Purchases of property and equipment | 48 | 314 | 244 | 383 |
| Net cash used in investing activities | -263,237 | -48,974 | -244 | 416 |
| Proceeds from stock option exercises and the issuance of shares under espp | NaN | 129 | 1,954 | 97 |
| Payment of issuance costs related to private placement | -1,067 | NaN | 643 | 551 |
| Proceeds from the issuance of common stock from underwritten public offering, net of underwriting discount and commissions | NaN | 108,101 | NaN | NaN |
| Proceeds from the issuance of pre-funded warrants | NaN | 0 | 0 | 175,000 |
| Payment of issuance costs related to underwritten public offering and private placements | NaN | 1,325 | NaN | NaN |
| Proceeds from the issuance of common stock from at-the-market sales agreement, net of issuance costs | NaN | 49,849 | 20,257 | 0 |
| Repurchases of shares for tax withholdings upon vesting of restricted stock unit awards | 2 | 148 | 19 | 87 |
| Proceeds from issuance of common stock in private placement | 74,999 | 149,999 | NaN | NaN |
| Net cash provided by (used in) financing activities | 74,870 | 307,799 | 21,549 | 174,459 |
| Net decrease in cash, cash equivalents and restricted cash equivalents | -226,613 | 236,024 | -32,357 | 108,625 |
| Cash, cash equivalents and restricted cash equivalents, beginning of period | 396,654 | 160,630 | 84,362 | NaN |
| Cash, cash equivalents and restricted cash equivalents, end of period | 170,041 | 396,654 | 160,630 | NaN |